(HLN) Haleon - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 40.616m USD | Total Return: -14.2% in 12m
Oral Care, Vitamins, Pain Relief, Respiratory Care, Digestive Health
Total Rating 48
Safety 75
Buy Signal -0.35
Drug Manufacturers - Specialty & Generic
Industry Rotation: -0.5
Industry Rotation: -0.5
Market Cap:
40.6B
Avg Turnover: 72.0M
Avg Turnover: 72.0M
Risk 3d forecast
Volatility19.3%
VaR 5th Pctl3.49%
VaR vs Median9.88%
Reward TTM
Sharpe Ratio-0.82
Rel. Str. IBD16.6
Rel. Str. Peer Group14.2
Character TTM
Beta-0.198
Beta Downside-0.378
Hurst Exponent0.497
Drawdowns 3y
Max DD23.11%
CAGR/Max DD0.24
CAGR/Mean DD0.72
EPS (Earnings per Share)
EPS CAGR: -4.90%
EPS Trend: -2.8%
EPS Trend: -2.8%
Last SUE: -0.22
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 17.07%
Rev. Trend: 83.4%
Rev. Trend: 83.4%
Last SUE: -0.14
Qual. Beats: 0
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Description: HLN Haleon
Haleon plc is a global consumer healthcare company specializing in the development and commercialization of over-the-counter (OTC) medicines, vitamins, and oral care products. The company manages a portfolio of established brands including Sensodyne, Advil, Centrum, and Flonase across major international markets. Originally formed as a joint venture between GSK and Pfizer, Haleon operates in a sector characterized by high brand loyalty and defensive cash flows, as consumer health spending tends to remain stable during economic cycles.
The business model relies on a combination of pharmaceutical-grade research and fast-moving consumer goods (FMCG) marketing strategies to maintain market share. Unlike pure-play pharmaceutical firms, consumer health companies face lower clinical trial risks but must navigate complex regulatory environments for non-prescription labeling and distribution. Investors should evaluate the companys long-term debt levels and margin stability on ValueRay to gain a clearer picture of its financial health. Headquartered in the United Kingdom, Haleon remains one of the largest standalone providers of consumer health products by revenue.
- Market share growth in power brands drives organic revenue and margin expansion
- Deleveraging progress enables future share buybacks and increased dividend payouts to shareholders
- GSK and Pfizer stake sell-downs create technical overhang on the stock price
- Shifting consumer spending toward private label alternatives threatens premium brand volume growth
- Regulatory scrutiny on product health claims impacts marketing efficacy and brand equity
Piotroski VR‑10 (Strict)
7.5
| Net Income: 2.78b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.48 > 1.0 |
| NWC/Revenue: -1.98% < 20% (prev -31.14%; Δ 29.16% < -1%) |
| CFO/TA 0.17 > 3% & CFO 5.43b > Net Income 2.78b |
| Net Debt (7.27b) to EBITDA (4.76b): 1.53 < 3 |
| Current Ratio: 0.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.48b) vs 12m ago -1.77% < -2% |
| Gross Margin: 63.76% > 18% (prev 0.61%; Δ 6.31k% > 0.5%) |
| Asset Turnover: 57.63% > 50% (prev 49.42%; Δ 8.22% > 0%) |
| Interest Coverage Ratio: 7.61 > 6 (EBITDA TTM 4.76b / Interest Expense TTM 557.5m) |
Altman Z''
5.37
| A: -0.01 (Total Current Assets 4.54b - Total Current Liabilities 4.92b) / Total Assets 32.57b |
| B: 0.85 (Retained Earnings 27.80b / Total Assets 32.57b) |
| C: 0.13 (EBIT TTM 4.24b / Avg Total Assets 33.44b) |
| D: 1.73 (Book Value of Equity 27.89b / Total Liabilities 16.12b) |
| Altman-Z'' Score: 5.37 = AAA |
Beneish M
-3.14
| DSRI: 0.98 (Receivables 2.12b/1.90b, Revenue 19.27b/16.96b) |
| GMI: 0.96 (GM 63.76% / 61.43%) |
| AQI: 0.86 (AQ_t 0.80 / AQ_t-1 0.93) |
| SGI: 1.14 (Revenue 19.27b / 16.96b) |
| TATA: -0.08 (NI 2.78b - CFO 5.43b) / TA 32.57b) |
| Beneish M-Score: -3.14 (Cap -4..+1) = AA |
What is the price of HLN shares?
As of May 21, 2026, the stock is trading at USD 9.28 with a total of 7,487,184 shares traded.
Over the past week, the price has changed by +2.88%, over one month by -4.13%, over three months by -16.57% and over the past year by -14.15%.
Over the past week, the price has changed by +2.88%, over one month by -4.13%, over three months by -16.57% and over the past year by -14.15%.
Is HLN a buy, sell or hold?
Haleon has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy HLN.
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HLN price?
| Analysts Target Price | 11.7 | 26.5% |
Haleon (HLN) - Fundamental Data Overview
as of 20 May 2026
Market Cap GBP = 30.22b (40.62b USD * 0.7441 USD.GBP)P/E Trailing = 18.7143
P/E Forward = 16.7504
P/S = 3.6823
P/B = 1.8113
P/EG = 2.3602
Revenue TTM = 19.27b GBP
EBIT TTM = 4.24b GBP
EBITDA TTM = 4.76b GBP
Long Term Debt = 7.66b GBP (from longTermDebt, last quarter)
Short Term Debt = 834.5m GBP (from shortTermDebt, last quarter)
Debt = 8.59b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.27b GBP (from netDebt column, last quarter)
Enterprise Value = 37.49b GBP (30.22b + Debt 8.59b - CCE 1.32b)
Interest Coverage Ratio = 7.61 (Ebit TTM 4.24b / Interest Expense TTM 557.5m)
EV/FCF = 13.61x (Enterprise Value 37.49b / FCF TTM 2.76b)
FCF Yield = 7.35% (FCF TTM 2.76b / Enterprise Value 37.49b)
FCF Margin = 14.30% (FCF TTM 2.76b / Revenue TTM 19.27b)
Net Margin = 14.43% (Net Income TTM 2.78b / Revenue TTM 19.27b)
Gross Margin = 63.76% ((Revenue TTM 19.27b - Cost of Revenue TTM 6.99b) / Revenue TTM)
Gross Margin QoQ = 65.03% (prev 64.51%)
Tobins Q-Ratio = 1.15 (Enterprise Value 37.49b / Total Assets 32.57b)
Interest Expense / Debt = 1.90% (Interest Expense 163.0m / Debt 8.59b)
Taxrate = 19.50% (208.7m / 1.07b)
NOPAT = 3.42b (EBIT 4.24b * (1 - 19.50%))
Current Ratio = 0.92 (Total Current Assets 4.54b / Total Current Liabilities 4.92b)
Debt / Equity = 0.52 (Debt 8.59b / totalStockholderEquity, last quarter 16.40b)
Debt / EBITDA = 1.53 (Net Debt 7.27b / EBITDA 4.76b)
Debt / FCF = 2.64 (Net Debt 7.27b / FCF TTM 2.76b)
Total Stockholder Equity = 16.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.31% (Net Income 2.78b / Total Assets 32.57b)
RoE = 17.26% (Net Income TTM 2.78b / Total Stockholder Equity 16.11b)
RoCE = 17.85% (EBIT 4.24b / Capital Employed (Equity 16.11b + L.T.Debt 7.66b))
RoIC = 13.61% (NOPAT 3.42b / Invested Capital 25.09b)
WACC = 4.46% (E(30.22b)/V(38.82b) * Re(5.29%) + D(8.59b)/V(38.82b) * Rd(1.90%) * (1-Tc(0.19)))
Discount Rate = 5.29% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -76.41 | Cagr: -1.45%
[DCF] Terminal Value 88.44% ; FCFF base≈2.47b ; Y1≈3.05b ; Y5≈5.21b
[DCF] Fair Price = 32.46 (EV 151.05b - Net Debt 7.27b = Equity 143.78b / Shares 4.43b; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -2.77 | EPS CAGR: -4.90% | SUE: -0.22 | # QB: 0
Revenue Correlation: 83.37 | Revenue CAGR: 17.07% | SUE: -0.14 | # QB: 0
EPS current Year (2026-12-31): EPS=0.56 | Chg30d=+0.69% | Revisions=+0% | GrowthEPS=+9.6% | GrowthRev=+3.2%
EPS next Year (2027-12-31): EPS=0.61 | Chg30d=-0.03% | Revisions=+0% | GrowthEPS=+9.4% | GrowthRev=+4.3%
[Analyst] Revisions Ratio: +0%